Results 191 to 200 of about 8,708 (251)

Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study.

Lancet. Infectious Diseases (Print)
BACKGROUND Ceftolozane-tazobactam and ceftazidime-avibactam are preferred treatment options for multidrug-resistant Pseudomonas aeruginosa infections; however, real-world comparative effectiveness studies are scarce.
R. K. Shields, Lilian M. Abbo, Renee Ackley, Samuel L. Aitken, Benjamin Albrecht, Ahmed Babiker, R. Burgoon, Renzo Cifuentes, K. Claeys, Brooke N Curry, Kathryn DeSear, Jason C Gallagher, Esther Y. Golnabi, Alan E. Gross, Jonathan Hand, Emily L Heil, K. Hornback, Keith S Kaye, Trieu-Vi Khuu, Megan E Klatt, Ellen G. Kline, Ryan C. Kubat, W. Kufel, Jae Hyoung Lee, A. Lepak, Ahmi Lim, Justin Ludwig, C. MacDougall, Anjali Majumdar, Amy J Mathers, E. McCreary, William R Miller, M. Monogue, W. Moore, Shannon Olson, Jessica Oxer, J. Pearson, Christine Pham, Paulette Pinargote, C. Polk, M. Satlin, S. Satola, Sunish Shah, P. Tamma, T. Tran, D. van Duin, M. VanNatta, Ana Vega, V. Venugopalan, M. Veve, W. Wangchinda, Lucy S Witt, Janet Y. Wu, J. Pogue   +53 more
semanticscholar   +1 more source

Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam

Antimicrobial Agents and Chemotherapy
Few studies compare outcomes of patients with difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam.
Dariusz A. Hareza, Sara E. Cosgrove, R. Bonomo, Kathryn Dzintars, S. Karaba, A. Hawes, Tsigereda Tekle, P. Simner, P. Tamma   +8 more
semanticscholar   +1 more source

Complex pathways to Ceftolozane-tazobactam resistance in clinical Pseudomonas aeruginosa isolates: a genomic epidemiology study

medRxiv
Objectives: We aimed to conduct a comprehensive genomic analysis of ceftolozane/tazobactam (C/T) resistance mechanisms in Pseudomonas aeruginosa by combining novel institutional data with publicly available sequencing data.
Hoai-An Nguyen, A. Peleg, Jiangning Song, J. Wisniewski, Luke V. Blakeway, G. Z. Badoordeen, Ravali Theegala, N. Q. Doan, Matthew H. Parker, D. Dowe, N. Macesic   +10 more
semanticscholar   +1 more source

Ceftolozane/tazobactam use and emergence of resistance: a 4-year analysis of antimicrobial susceptibility in Pseudomonas aeruginosa isolates in a tertiary hospital

Frontiers in Microbiology
Background Ceftolozane/tazobactam (C/T) was temporarily withdrawn from December 2020 to February 2022: this forced unavailability created the conditions to study how drug discontinuation might influence Pseudomonas aeruginosa (PA) resistance ...
Alessandra Imeneo, L. Campogiani, P. Vitale, Andrea Di Lorenzo, Grazia Alessio, Davide Natale Abate, Maria Grazia Celeste, Anna Altieri, C. D’Agostini, V. Malagnino, M. Andreoni, Marco Iannetta, L. Sarmati   +12 more
semanticscholar   +1 more source

A real-world investigation into prescribing patterns and effectiveness of ceftolozane/tazobactam among critically ill patients from SPECTRA.

Diagnostic microbiology and infectious disease
BACKGROUND Ceftolozane/tazobactam (C/T) real-world use was examined in a global population of critical care patients treated in intensive care unit settings.
A. Soriano, David L Paterson, F. Thalhalmmer, S. Kluge, Pierluigi Viale, B. Akrich, M. Allen, Stephanie Wirbel, Alexandre H. Watanabe, Emre Yücel, E. Obi, Sundeep Kaul   +11 more
semanticscholar   +1 more source

Ceftolozane-Tazobactam Versus Ceftazidime-Avibactam for the Treatment of Infections Caused by Multidrug-Resistant Pseudomonas aeruginosa: a Multicenter Cohort Study

Antimicrobial Agents and Chemotherapy, 2023
Ceftolozane-tazobactam (C-T) and ceftazidime-avibactam (CAZ-AVI) are two novel antimicrobials that retain activity against resistant Pseudomonas aeruginosa. The comparative effectiveness and safety of C-T versus CAZ-AVI remain unknown.
Thamer A. Almangour, Leen Ghonem, Dareen Alassiri, Alanoud Aljurbua, Mohammed Al Musawa, Amin Alharbi, Abdullah Almohaizeie, Sara Almuhisen, Jeelan Alghaith, Nader Damfu, Doaa Aljefri, Wafa Alfahad, Yaqoub Khormi, Menyfah Q. Alanazi, Y. Alsowaida   +14 more
semanticscholar   +1 more source

Multi-Drug Resistant Gram-Negative Sepsis in Neonates: The Special Role of Ceftazidime/Avibactam and Ceftolozane/Tazobactam

Medicines
Neonatal sepsis is a major cause of morbidity and mortality in neonates. A particular concern is the increasing prevalence of antibiotic-resistant strains among neonatal intensive care units (NICUs).
N. Dermitzaki, Foteini Balomenou, A. Serbis, Natalia Atzemoglou, Lida-Eleni Giaprou, Maria Baltogianni, V. Giapros   +6 more
semanticscholar   +1 more source